Dong-A St (170900) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.012x

Based on the latest financial reports, Dong-A St (170900) has a cash flow conversion efficiency ratio of 0.012x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩8.17 Billion ≈ $5.53 Million USD) by net assets (₩676.02 Billion ≈ $458.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Dong-A St - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Dong-A St's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 170900 current and long-term liabilities for a breakdown of total debt and financial obligations.

Dong-A St Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Dong-A St ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Anora Group Oyj
HE:ANORA
0.266x
First Community Corporation
NASDAQ:FCCO
0.057x
Cymechs Inc
KQ:160980
0.045x
Media and Games Invest PLC
ST:M8G
0.011x
OVB Holding AG
XETRA:O4B
0.033x
Polyplex (Thailand) Public Company Limited
BK:PTL
0.032x
Blue Foundry Bancorp
NASDAQ:BLFY
-0.001x
FutureChem Co.Ltd
KQ:220100
-0.028x

Annual Cash Flow Conversion Efficiency for Dong-A St (2013–2024)

The table below shows the annual cash flow conversion efficiency of Dong-A St from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Dong-A St market cap and net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩708.81 Billion
≈ $480.35 Million
₩-11.79 Billion
≈ $-7.99 Million
-0.017x -436.74%
2023-12-31 ₩683.31 Billion
≈ $463.07 Million
₩3.37 Billion
≈ $2.29 Million
0.005x -89.64%
2022-12-31 ₩690.11 Billion
≈ $467.68 Million
₩32.89 Billion
≈ $22.29 Million
0.048x -36.63%
2021-12-31 ₩656.38 Billion
≈ $444.82 Million
₩49.37 Billion
≈ $33.46 Million
0.075x +78.68%
2020-12-31 ₩642.10 Billion
≈ $435.14 Million
₩27.03 Billion
≈ $18.32 Million
0.042x -51.67%
2019-12-31 ₩645.86 Billion
≈ $437.69 Million
₩56.25 Billion
≈ $38.12 Million
0.087x +0.65%
2018-12-31 ₩579.36 Billion
≈ $392.63 Million
₩50.14 Billion
≈ $33.98 Million
0.087x -1.83%
2017-12-31 ₩581.19 Billion
≈ $393.87 Million
₩51.23 Billion
≈ $34.72 Million
0.088x +2648.88%
2016-12-31 ₩589.22 Billion
≈ $399.31 Million
₩1.89 Billion
≈ $1.28 Million
0.003x -95.81%
2015-12-31 ₩553.77 Billion
≈ $375.28 Million
₩42.40 Billion
≈ $28.73 Million
0.077x -55.88%
2014-12-31 ₩488.34 Billion
≈ $330.94 Million
₩84.75 Billion
≈ $57.43 Million
0.174x +546.86%
2013-12-31 ₩439.36 Billion
≈ $297.75 Million
₩-17.06 Billion
≈ $-11.56 Million
-0.039x --

About Dong-A St

KO:170900 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$275.09 Million
₩405.93 Billion KRW
Market Cap Rank
#15332 Global
#573 in Korea
Share Price
₩44300.00
Change (1 day)
-1.12%
52-Week Range
₩42450.00 - ₩57800.00
All Time High
₩155894.20
About

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. For lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bl… Read more